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Introduction
Antiviral therapy of chronic hepatitis B virus (HBV) infection remains a serious clinical problem. Several trials have shown that a sustained response ta interferon alpha or to nucleoside analogues is observed in only 30-40% of selected patients (Marcellin et al., 1989; Perillo et al., 1990; Zoulim & Trepo, 1994; Dienstag et al., 1995) . This response rate is even lower in long-term HBV carriers and in immunocompromised patients. Since the majority of patients will not clear the viral infection and will be at risk of developing liver cirrhosis and hepatocellular carcinoma, the design of new protocols for chemotherapy of chronic HBV infections is still needed (Robinson et al., 1990) . The development of new nucleoside analogues, with a potent anti-HBV activity and minimal cytotoxic effect, such as guanosine analogues (Schalm et al., 1985; Price et al., 1989; Fourel et al., 1994a,b; Sommadossi 1994; Hafk.emeyer etal., 1996; Howe et al., 1996) may provide a promising alternative for the therapy of chronic hepatitis B. Recently, the purine nucleoside analogue, penciclovir (9-(4-hydroxy-3-hydroxymethylbut-I-yl)guanine; BRL 39123), which is a highly selective antiviral agent, having activity against herpesviruses (Boyd et al., 1987; Vere Hodge and Perkins, 1989; Earnshaw et al., 1992) , was also shown to have a potent anti-hepadnavirus activity in the animal models of HBV infection (Shaw et al., 1994; Tsiquaye et al., 1994; Lin et al., 1996) . Penciclovir was shown to inhibit duck hepatitis B virus (DHBV) replication in vitro in primary duck hepatocytes infected with DHBV (Shaw et al., 1994) and to be a selective inhibitor of HBV replication in cultured human hepatoblastoma cells (Korba and Boyd, 1996) . Furthermore, results of in vivo experiments showed that the intraperitoneal administration ofpenciclovir induced a profound inhibition of viral DNA and protein synthesis in ducks congenitally infected with DHBV . Famciclovir, its oral form, was also shown to inhibit viral replication in congenitally DHBV-infected ducklings (Tsiquaye et al., 1994 (Tsiquaye et al., , 1996 . Preliminary evidence suggests that famciclovir may have clinical utility in the treatment of chronic HBV-infected patients (Main et al., 1996) and of HBV recurrence after orthotopic liver transplantation (Kruger et al,1996) In view of the low cytotoxicity of penciclovir and its potent antiviral activity against HBV, it is important to gain a better understanding of the mechanism of inhibition of HBV replication. The HBV polymerase is the main target for nucleoside analogues, but has multiple functions including the requirement for viral pregenome encapsidation, RNA-dependent DNA synthesis, DNAdependent DNA synthesis, and RNase-Hactivity (Seeger et al., 1991) . Recently, Wang and Seeger developed an in vitro assay for the expression of the DHBV reverse transcriptase and showed that this viral enzyme exhibits reverse transcriptase activity and acts as a primer for DNA synthesis Seeger, 1992, 1993) . It was demonstrated that, unlike all the other known reverse transcriptases, the DHBV polymerase uses the hydroxyl group of a conserved tyrosine residue as a primer for DNA synthesis. Viral DNA synthesis is initiated by the formation of a covalent bond between the polymerase and dGMP, followed by the addition of other nucleotides (T-A-A) in a template-dependent manner Seeger, 1992, 1993; . Viral DNA chain is further extended by the addition of deoxynucleotides by the DHBV polymerase. This in vitro model for the detailed study of reverse transcription in hepadnaviruses provides a new tool for the characterization of the mechanism of action of new anti-HBV polymerase inhibitors and especially of anti-priming compounds Seeger 1992, 1993; Staschke and Colacino, 1994; Aguesse et al, 1996) . Using this assay, it has recently been demonstrated that cytidine-triphosphate analogues are indeed inhibitors of hepadnavirus reverse transcription .
For these reasons, this in vitro assay was used to characterize the mechanism of the inhibitory activity of penciclovir-triphosphate, in comparison with other guanosine analogue nucleotides, on hepadnavirus reverse transcription. Evidence is provided that penciclovir-triphosphate, an anti-herpesvirus compound, inhibits hepadnavirus reverse transcription, in a chiral dependent manner, by inhibiting both the synthesis of the short DNA primer and the elongation ofviral DNA. Penciclovir-TP inhibits DHBV reverse transcription acyclovir-triphosphate (ACV-TP) were kindly provided by M Boyd (SmithKline Beecham Pharmaceuticals, UK). Both enantiomers of PCV-TP were prepared in the laboratories of SmithKline Beecham Pharmaceuticals. The enantiomers of 4'-Ovbenzyl-PCV were separately synthesized with known absolute config-' uration to an enantiomeric excess of 90%. Subsequent phosphorylation, de-benzylation and purification by ion exchange chromatography on DEAE Sephadex afforded the triethylammonium salts of(R) and (S)-PCV-TP. On the assumption that no racemization has occurred in these final steps, the enantiomeric excess of the triphosphates should also be 90%, and they were found to have equal and opposite rotations ([a]20 11.0 deg.L dm.mol-1 (c=2.0 mM) for (R)-PCV-TP and [a]20 -11.5 deg.L dm.mol-1 (c=2.0 mM) for (S)-PCV-TP; Jarvest RL et al., personal communication). The triphosphate form of 2',3'-dideoxyguanosine (ddG-TP) was purchased from Boehringer Mannheim. Carbocyclic 2'-deoxyguanosine-TP (CDG-TP) was a generous gift from William Mason (Fox Chase Cancer Center, Philadelphia, USA).
Materials and Experimental Procedures

Plasmid constructs
Plasmid pHP contains the DHBV polymerase gene under the control of the Sp6 promoter and the sequence coding for the RNA template of reverse transcription as already described previously Seeger, 1992, 1993; . In addition the polymerase gene was expressed together with pMscI-SL, a plasmid which expresses an RNA sequence which contains the 3'-hairpin structure (E) of the pregenome encapsidation signal, DR1, and the template for the synthesis of the first 162 nucleotides of minus strand DNA Wang et al., 1994) (Fig. 1, panel A ).
An in vitro assay for the expression of enzymatically active DHBV reverse tra nscriptase
The polymerase gene was transcribed and translated in a coupled transcription/translation rabbit reticulocyte lysate system (TNT Coupled Reticulocyte System, Promega), according to manufacturer's instructions. Reverse transcriptase reaction was performed mainly as previously described Seeger, 1992, 1993; Zoulim et al., 1996) , after incubation of the translation mixture at 30°C for 30 min with an equal volume of a reaction mixture containing 100 mM Tris-HCl pH 7.5, 30 mM NaCl, 20 mM MgC~, and [a-32 P]dGT P (3000 Ci mmol", 0.30 flM).
For priming assays, the reactions were performed only with radiolabelled dGTP (0.15 flM, final concentration) and therefore allowed the formation of a covalent bond between the viral polymerase and the first nucleotide of minus strand DNA, [a-32 P]dGT P. For reverse transcription assays, the reaction was performed in the presence of each cold deoxynucleotide-TP (dNTPs) except dGTP (100~tM, final concentration) and radiolabel1ed
[a_ 32 p ] dGTP, to study the elongation of viral minus strand DNA beyond the first dGTP covalently attached to the viral polymerase. Inhibitors were added at the indicated concentrations.
Radiolabel1ed viral DNA covalently attached to polymerase was analysed through 0.1% SDS-10% polyacrylamide gels as already published (Wang and Seeger, 1992; . This provided a qualitative assay for the analysis ofviral DNA. A quantitative dot assay was performed after spotting the reverse transcriptase assay reaction on DE-81 filters (Whatman) . The paper was then washed and radioactivity was measured in a Beckman LS 6000SC scintillation counter. In each assay,background incorporation was calculated with a control experiment where the reaction was performed as described above but without addition ofplasmid pHP (negative control). For each condition tested (without inhibitor or positive control, and each concentration of inhibitor), the actual incorporation of deoxynucleotides in viral minus strand DNA was estimated by the difference in c.p.m. between the test experiment and the negative control (background incorporation). All results were then expressed in percentage of inhibition as compared to the reaction where the polymerase was incubated without any inhibitor (positive control). Comparison between densitometric scanning of autoradiogram and experiment with DE81 filter showed similar results.
Analysis of viral DNA primer synthesis
To analyse viral DNA primer synthesis, the DHBV polymerase was incubated with different concentrations of guanosine analogues together with TIP and [a_ 32 p ] dATP (3000 Ci mmol'", 0.15~final concentration). Reactions were analysed through a 0.1% SDS-10% polyacrylamide gel and autoradiographed. The level of [a-32p]dATP incorporation in the short DNA primer was analysed by a spot assay on DE-81 fIlters.The kinetics of [a-32 P]dAMP incorporation was also analysed in the presẽ nce of dGTP analogues (100~) and TIP (100~). 
Results
An in vitro assay for the study of DHBV reverse transcriptase inhibitors
It was previously shown that the DHBV polymerase expressed in vitro in a reticulocyte lysate is enzymatically active ifthe RNA template for the initiation of reverse transcription (Fig. La) is provided during the translation of the viral enzyme Seeger, 1992, 1993; Wang et al., 1994) . As shown in Fig. 1 (b) , the priming reaction corresponds to enzymatic reactions performed in the presence of [a-32 P]dGT P but in the absence of other dNTPs, and results in the incorporation of [a-32p]dGTP in the DHBV polymerase. The extension of viral minus strand DNA corresponds to enzymatic reactions performed in the presence of [a-32 P]dGT P and the other cold dNTPs (dNTP-G), and results in a retardation of electrophoretic mobility of the DHBV polymerase covalently linked to the nascent viral DNA chain. The incorporation of radiolabelled dGTP in the elongation reaction was approximately 20-times higher than in the priming reaction, suggesting that 20 guanosines were incorporated beyond the first one (estimated DNA chain length of 80 nucleotides) (data not shown).
Inhibitory effect of guanosine analogue triphosphates on the elongation of viral minus strand DNA
The mean percentage of inhibition of [a-32P]dGTP incorporation in viral minus strand DNA, analysed by a spot assay on DE-Bl filters, is plotted on a semi-logarithmic scale (mean of 3 experiments).
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We have compared the inhibitory activity of the triphosphate form of guanosine analogues on the elongation of viral minus strand DNA. Fig. 2 shows the results of a typical experiment. Viral DNA chain covalently linked to the viral polymerase was analysed through 0.1% SDS~10% polyacrylamide gels ( Fig. 2a ). As shown in Fig. 2 flM, ACV-TP and (R)-PCV-TP showed a significant inhibitory effect (72%, and 56% of inhibition, respectively). (S)-PCV-TP was the less active compound and concentrations higher than 100 flM were needed to achieve a significant inhibition of reverse transcription (data not shown). CDG-TP was the most active compound since the same order of inhibition could be obtained at a concentration of 1 flM. The level ofviral DNA synthesis was measured by the incorporation of dNTPs (dATP, TIP, dCTP) and radiolabelled [a-32 PJ-dGT P in a dot assay on DE-81 filters.The mean inhibition of dGTP incorporation is shown in Fig. 2 (b) , and the IC so of ACV-TP, (R)-PCV-TP, and CDG-TP was 11 flM (± 5 flM SD), 20 flM (± 9 flM SD), and 0.5 flM (± 0.1 mM SD), respectively. (S)-PCV-TP was less efficient than (R)-PCV-TP, with an IC so higher than 90 11M.
Effect of guanosine analogue triphosphates on the incorporation of the first nucleotide of minus strand DNA, dGMP (priming of reverse transcription)
In the next experiment, the inhibitory effect of these different analogues on DNA-priming (i.e., incorporation of the first nucleotide of minus strand DNA, dGMP) was tested. The DHBV polymerase was incubated with only [a-32 PJdGT P (0.15 flM final concentration, 3000 Ci mmol"), ACV-TP, (R)-PCV-TP, (S)-PCV-TP, and CDG-TP were tested in the same range of concentrations ( Fig. 3) . ACV-TP and (R)-PCV-TP inhibited the incorporation of the first nucleotide, dGTP, with IC so of 42 flM and 38 flM, respectively, which were higher than those obtained with the DNA chain elongation. (R)-PCV-TP was a more effective inhibitor of the priming reaction than (S)-PCV-TP which had an IC so higher than 100 flM. CDG-TP was the most potent inhibitor of dGTP incorporation (IC so <l 11M), since the inhibition was almost complete at a concentration of 10 11M. We then examined whether guanosine analogues can inhibit the incorporation of the next nucleotide in the short DNA primer (Fig. 4) . In DHBV, the DNA primer sequence is G-T-A-A . Therefore the reactions were performed after the incubation of the viral polymerase with dGTP analogues, TIP and radiolabelled [a-32 PJdAT P (3000 Ci mmol", 0.15 flM final concentration). The incorporation of radiolabelled dATP increased and reached a plateau in the presence of increasing amounts of dGTP. CDG-TP, which was the most potent competitor for dGTP incorporation, did not inhibit significantly the incorporation of radiolabelled dATP. Fig. 4 shows that ACV-TP, (R)-PCV~TP, (S)-PCV-TP inhibited reproducibly and profoundly the formation of the short DNA primer following their incorporation, even at low concentration (1 flM). ddG-TP showed an inhibitory effect at higher concentrations (10 flM). We then analysed the kinetics . ... . , , " . : _.,....•" ' . Penciclovir, a new guanosine analogue active against herpesvirus (Boyd et al., 1987 (Boyd et al., , 1993 Vere Hodge and Perkins 1989; Saltzman et al., 1994) , has been shown to inhibit both HBV and DHBV replication, in vitro in cul- The results of DNase I digestion of radiolabelled DNA products covalently linked to DHBV polymerase showed that this was not entirely due to the presence of endogeneous dNTPs in the reticulocyte lysate, but suggested that a minority of the DHBV polymerase polypeptides may prime reverse transcription directly from dAMP in our in vitro conditions (Fig. 6) . Indeed, DNase I digestion of DNA products labelled with [a-32 P]dGT P or with [a-32 P]dAT P showed a similar pattern with the persistence of only primed products and the disappearance of the extended products, demonstrating that dGTP and also dATP can be incorporated in strand DNA and of DNA chain elongation. Interestingly, the two PCV-TP enantiomers did not inhibit the DHBV reverse transcription with the same efficacy. (R)-PCV-TP was the most active enantiomer against hepadnavirus reverse transcriptase whereas (S)-PCV-TP is the more active against herpesvirus DNA polymerase (Earnshaw et al., 1992) . It appears that (R)-PCV-TP is also the more active enantiomer against the HIV reverse transcriptase (Lesnikowski et al., 1994) and the core particle derived HBV DNA polymerase activity (S Mok, T Shaw, S Locarnini, personal communication) . These observations suggest that once phosphorylated inside the cell, the enantiomer of PCV-TP could be a critical factor if inhibition of viral minus strand DNA synthesis is the only target for PCV-TP. In our in vitro conditions, the efficiency of nucleoside analogue phosphorylation and the intracellular half-life of the nucleoside analogue triphosphates in infected hepatocytes are not taken into account. Preliminary results with the DHBV polymerase expressed in vitro suggest that (R)-PCV-TP is likely to be a competitive inhibitor of dGTP incorporation as was also observed with the HBV DNA polymerase activity (S Mok, T Shaw, S Locarnini, personal communication) . The effect on the formation of the DNA primer for viral minus strand DNA elongation was then investigated. Interestingly, CDG-TP, which was the most potent competitor of the incorporation of the first nucleotide of minus strand DNA, did not significandy inhibit the incorporation of the third nucleotide of viral minus strand DNA, dAMP (Fig. 4 ). This suggests that CDG-TP does not act as an obligate, or absolute, chain terminator. This is consistent with the observation of Parker et al. (1992) with the HIV reverse transcriptase, who showed that the DNA chain can be poorly extended beyond the incorporation of CDG-TP. Although acyclic guanosine analogue triphosphates showed a weaker inhibition of dGTP incorporation as compared to CDG-TP (Fig. 2, 3) , they did inhibit dramatically the incorporation of the next nucleotides (Fig. 4, 5) . In this assay, ACV-TP and the (R) and (S) enantiomers ofPCV-TP were equally effective as inhibitors of the synthesis of the short DNA primer. The potent activity ofboth PCV-TP enantiomers in this assay (IC so <l flM) suggests that this may be a key target for these compounds in their mode of action against hepadnaviruses (Fig. 4, 5) . These findings are consistent with the observation that, in herpesvirus infected cells, PCV-TP inhibits viral replication by causing premature chain termination after incorporation by the herpesvirus polymerase into viral DNA (Earnshaw et al., 1992) . It remains to be demonstrated that PCV-TP is indeed covalently attached to the DHBV polymerase or inhibits primer formation by not acting as an alternative substrate for dGTP (Arts and
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tured hepatocytes, and in vivo in animal models ofHBV infection (Shaw et al., 1994; Tsiquaye et al., 1994 Tsiquaye et al., , 1996 Korba and Boyd, 1996; Lin et al., 1996) . It was also shown that K i for HBV DNA polymerase contrast with high K., for cellular polymerase giving rise to high selectivity (Korba and Boyd, 1996) . The anti-HBV activity of its oral form, famciclovir, was also confirmed in patients chronically infected with HBV (Kruger et al., 1996; Main et al., 1996) . However the precise mode of action of penciclovir was not reported. Here, the inhibitory effect of penciclovir-triphosphate in an in vitro assay was analysed using an enzymatically active DHBV polymerase (Wang and Seeger, 1992) and its mechanism of inhibition of DHBV reverse transcription was investigated .
Using this assay,we examined the molecular mechanism of action of antiviral compounds known to inhibit hepadnavirus replication both in vivo and in vitro in tissue culture cells, and studied the anti-HBV effect of guanosine analogues since they may represent specific inhibitors of the priming of reverse transcription without affecting cellular functions. Acyclic analogues (triphosphates of PCV and ACV) showed a concentrationdependent inhibitory effect against the incorporation of dGTP in viral minus strand DNA by the DHBV reverse transcriptase. It was also shown that the carbocylic derivative, CDG-TP and acyclic guanosine analoguetriphosphates are indeed inhibitors of the RNA-dependent DNA synthesis in hepadnaviruses (Fig. 2, 3 ). Among these, CDG-TP, was the most potent inhibitor of the incorporation of the first nucleotide of minus Wainberg, 1996) . Further experiments using radiolabelled PCV-TP are required to determine whether either enantiomer of PCV-TP can form a covalent bond with the viral polymerase through a specific tyrosine residue, as was suggested by Howe et al. (1996) for ddGTP. However, the inhibition of the synthesis of the short DNA primer was not complete. The results of further experiments with DNase I digestion of viral DNA covalently linked to the DHBV polymerase suggested that some of the DHBV polymerase polypeptide may prime reverse transcription directly by the formation of a covalent bond with dATP instead of dGTP in the first position (Fig. 6) . The same observation was already made with both the DHBV and the HBV polymerases (Staschke and Colacino, 1994; Lanford et al., 1995) and may explain, at least in part, why guanosine triphosphate analogues could not inhibit completely the synthesis of the short DNA primer. This result suggests a potential advantage of new anti-HBV strategies using a combination of nucleoside analogues with different modes of action on the HBV replication cycle.
In this in vitro study of acyclic guanosine analogues known to have activity against herpesvirus replication, it has been shown that ACV-triphosphate and both enantiomers of PCV-triphosphate inhibit hepadnavirus reverse transcription through the inhibition of the synthesis of the short DNA primer. These data confirm the activity of their respective nucleosides, which have a validated anti-HBV action in vivo and in tissue culture (Schalm et al., 1985; Ueda et al., 1989; Shaw et al., 1994; Tsiquaye et al., 1994 Tsiquaye et al., , 1996 Howe etal., 1996; Korba and Boyd, 1996; Kruger et al., 1996; Main et al., 1996) . Penciclovir is a highly selective antiviral agent, having activity against herpesviruses (Boyd et al., 1987) and hepadnaviruses (Shaw et al., 1994; Tsiquaye et al., 1994) but being non-toxic to replicating cells (Vere Hodge and Perkins 1989; Boyd et al., 1993) . In clinical trials famciclovir has a safety profile comparable to that of placebo (Saltzman et al., 1994) and is being further evaluated clinically as an anti-HBV agent (Kliiger et al., 1996; Main et al., 1996) . Our studies suggest that the selective activity of famciclovir against HBV results from inhibition both of the formation of the viral DNA primer and the elongation of viral minus strand DNA.
